Novartis
EMA's CHMP Recommends Novartis' Scemblix for TKI-Intolerant Chronic Myeloid Leukemia Patients
The committee recommended the STAMP inhibitor for previously treated Philadelphia chromosome-positive CML patients based on data from the ASCEMBL trial.
MD Anderson Study Explains Differing BRAF/MEK Treatment Responses in Male, Female Melanoma Patients
Premium
If validated, the findings could inform strategies for improving responses to BRAF/MEK inhibitors including using androgen receptor blockers.
Novartis Nets Tumor-Agnostic Approval for Tafinlar-Mekinist Combo
The accelerated approval makes the combination available to patients with any refractory tumor harboring a BRAF V600E mutation, except for those with colorectal cancer.
European Commission Approves Novartis MET Inhibitor Tabrecta for Advanced NSCLC
The agent is approved for non-small cell lung cancer patients in Europe whose tumors harbor METex14 skipping and who received prior immunotherapy and/or chemo.
Ratio Therapeutics Launches to Develop More Target-Specific, Less Toxic Radiopharmaceuticals
Premium
The first test of its radiopharmaceutical technology will be in PSMA-positive prostate cancer, which is poised to enter the clinic later this year.